Inactive Instrument

Other languages Intrexon Corp Nyse

Equities

US46122T1025

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	Apr. 24
Precigen Shares Fall After Downgrade From JPMorgan	Mar. 22
Precigen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19
Precigen's Investigational RRP Therapy Gets Orphan Drug Designation in Europe	Jan. 16
Precigen, Inc. Receives Orphan Drug Designation for PRGN- 2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission	Jan. 16
Precigen Q3 Net Loss Widens, Revenue Falls	Nov. 09
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Insider Buy: Precigen	23-08-16
Insider Buy: Precigen	23-08-15
Precigen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Precigen, Inc Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval	23-08-09
Precigen Gets US FDA Grants Breakthrough Therapy Designation to PRGN-2012 for Recurrent Respiratory Papillomatosis Treatment	23-06-20
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerseâ„¢ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis	23-06-20
Precigen Unveils Positive Phase 1 Data From Advanced Stage Platinum Resistant Ovarian Cancer Patients	23-06-05
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients	23-06-05
Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers	23-06-03
Sector Update: Health Care Stocks Advancing Late Wednesday	23-05-31
Sector Update: Health Care Stocks Higher in Afternoon Trading	23-05-31
Sector Update: Health Care	23-05-31
Precigen Gets FDA Clearance for Phase 2 Study of Cervical Cancer Combination Treatment	23-05-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Intrexon Corp Nyse

Equities

US46122T1025

Other languages

Filters